Supporting information
Table 1. Patients’ characteristics
Table 2. Grade of adverse events reported by patients with Veregen® and placebo treatment
Figure 1. Kaplan-Meir plot showing time to clinical resolution of uVIN lesions in Veregen® and placebo.
Figure 2a. McGill Pain score reported by patients over time at baseline and after starting Veregen® and placebo treatment.
Figure 2b: Dermatology Quality of Life (QLDI) score reported by patients over time at baseline and after starting Veregen® and placebo treatment.